Danielle E Hammond, MD, FRCP(C) HEMATOLOGY
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | University of Ottawa, Ottawa, CA, MD |
Postgraduate Training
| 2019-2021 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2019 | Clinical Residency, Adult Hematology, Queen's University, Kingston |
| 2014-2017 | Clinical Residency, Internal Medicine, University of Toronto, Toronto |
Board Certifications
| 2019 | The Royal College of Physicians and Surgeons of Canada Certification in Adult Hematology |
| 2018 | The Royal College of Physicians and Surgeons of Canada Certification in Internal Medicine |
| 2016 | Licentiate, Medical Council of Canada |
| 2014 | United States Medical Licensing Exam, Step 2 Clinical Knowledge |
Experience & Service
Other Appointments/Responsibilities
Chief Leukemia Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2021
Co-chief Hematology Resident, Queen’s University, Kingston, 2018 - Present
Honors & Awards
| Dr. D. Carlton Williams President's Entrance Scholarship, Western University, London, ON | |
| New Member of the Year, Science Students’ Council, Western University, London, ON | |
| J.A.F. Stevenson Medal, Western University, London, ON | |
| Physician Kudos Award, The Ottawa General Hospital, Ottawa, ON | |
| Outstanding Clinical Performance, Core Internal Medicine Clerkship Rotation, The Ottawa General Hospital, Ottawa, ON | |
| Department of Medicine Teaching Award, Sunnybrook Health Sciences Centre, Toronto, ON | |
| Alexion Canada Honorarium, Canadian Fellows Program, ASH 2017 Annual General Meeting, Atlanta, GA | |
| Resident Prize for Excellence in Undergraduate Teaching, Nominee, Queen’s University, Kingston, ON | |
| Canadian National Hematology Trainee Quality Improvement Award | |
| Best Clinical Fellow, Leukemia Fellowship Program 2019-2020, The University of Texas MD Anderson Cancer Center | |
| ASH 2020 Abstract Achievement Award, ASH | |
| Best Overall Fellow, Leukemia Fellowship Program 2020-2021, The University of Texas MD Anderson Cancer Center | |
| ASCO 2021 Conquer Cancer Abstract Merit Award, ASCO |
Selected Publications
Peer-Reviewed Articles
- Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. PMID: 38896064.
- Sasaki, K, Kantarjian, HM, Montalban Bravo, G, Hammond, DE, Jabbour, EJ, Kanagal Shamanna, R, Chien, KS, Garcia-Manero, G. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(9):629-633, 2024. PMID: 38777652.
- Montalban Bravo, G, Jabbour, EJ, Chien, KS, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Daver, N, Kanagal-Shammana, R, Loghavi, S, Qiao, W, Huang, X, Schneider, H, Meyer, M, Kantarjian, HM, Garcia-Manero, G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142, 2024. PMID: 38744144.
- Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances 8(11):2695-2706, 2024. PMID: 38513082.
- Fiskus, WC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Mill, CP, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Reville, PK, Wang, J, Loghavi, S, Sen, R, Ruan, X, Su, X, Flores, L, DiNardo, C, Bhalla, K. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. PMID: 38437498.
- Bazinet, A, Desikan, SP, Li, Z, Rodriguez-Sevilla, JJ, Venugopal, S, Urrutia, S, Montalban Bravo, G, Sasaki, K, Chien, KS, Hammond, DE, Kanagal Shamanna, R, Ganan Gomez, I, Kadia, TM, Borthakur, G, DiNardo, C, Daver, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research 30(7):1319-1326, 2024. PMID: 38300723.
- Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, Kadia, TM, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 11(3):e186-e195, 2024. PMID: 38316133.
- Chien, KS, Ong, F, Kim, K, Li, Z, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Montalban Bravo, G, Hammond, DE, Sasaki, K, Pierce, SA, Kantarjian, HM, Garcia-Manero, G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer medicine 13(5), 2024. PMID: 38497538.
- Montalban Bravo, G, Jabbour, EJ, Borthakur, G, Kadia, TM, Ravandi-Kashani, F, Chien, KS, Pemmaraju, N, Hammond, DE, Dong, XQ, Huang, X, Schneider, H, John, RB, Kanagal-Shamana, R, Loghavi, S, Kantarjian, HM, Garcia-Manero, G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology 204(3):898-909, 2024. PMID: 37946611.
- Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. PMID: 37441846.
- Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. PMID: 37608562.
- Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. PMID: 37665752.
- Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
- DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2022. PMID: 35973199.
- Gener-Ricos, G, Gerstein, YS, Hammond, DE, DiNardo, C. Germline Predisposition to Myelodysplastic Syndromes. Cancer Journal (United States) 29(3):143-151, 2023. PMID: 37195770.
- Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol 98(4):E91-E94, 2023. e-Pub 2023. PMID: 36661399.
- Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2022. PMID: 36458426.
- Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
- Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. PMID: 36163957.
- Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. PMID: 36163972.
- Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. PMID: 36163960.
- Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6(13):3879-3883, 2022. PMID: 35511730.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2020. PMID: 33156969.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of Venetoclax-Based Therapy in Chronic Myelomonocytic Leukemia. Leukemia. None, 2021. PMID: 33846541.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. None, 2020. PMID: 33156969.
- Lamarche MC, Hammond D, Hopman W, Sirosky, #8208, Yanyk A, Shepherd L, Bhella SD. Can We Transfuse Wisely in Patients Undergoing Chemotherapy for Acute Leukemia or Autologous Stem Cell Transplantation?. Transfusion 59(7):2308-2315, 2019. PMID: 31059586.
- Gándara E, Hammond D, Nagpal S. Role of Vitamin K Antagonists in the Prevention of Thrombotic Bypass Occlusion After Infrainguinal Venous Bypass. None, 2016. PMID: 27142190.
- Mouhayar E, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. . Reversible Myocardial Edema Secondary to Tagraxofusp-induced Capillary Leak Syndrome. JACC: CardioOncology. PMID: None.
Invited Articles
- Hammond D, Montalban-Bravo G. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia. None, 2021. PMID: None.
- Hammond D, Loghavi S. Clonal Haematopoiesis of Emerging Significance. None, 2021. PMID: 33685721.
- Hammond D, Pemmaraju N. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. None, 2020. PMID: 32336420.
Other Articles
- Chiu CY, Matsuo T, Wurster S, Gerstein Y, Hammond DE, Chien KS, DiNardo C, Kontoyiannis DP Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency. Mycoses 66(12):1029-1034, 2023. PMID: 37550272.
- Cuglievan, B, Connors, JS, He, J, Khazal, SJ, Yedururi, S, Dai, J, Garces, S, Quesada, AE, Roth, M, Garcia, M, McCall, DC, Gibson, A, Ragoonanan, D, Petropoulos, D, Tewari, P, Nunez, CA, Mahadeo, KM, Tasian, SK, Lamble, AJ, Pawlowska, A, Hammond, DE, Maiti, A, Haddad, FG, Senapati, J, Daver, N, Gangat, N, Konopleva, M, Meshinchi, S, Pemmaraju, N Blastic plasmacytoid dendritic cell neoplasm. Leukemia 37(9):1767-1778, 2023. PMID: 37452102.
- Vuong, NN, Hammond, DE, Kontoyiannis, DP Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease. Journal of Fungi 9(4), 2023. PMID: 37108918.
- Santanelli di Pompeo F, Clemens MW, Atlan M, Botti G, Cordeiro PG, De Jong D, Di Napoli A, Hammond D, Haymaker CL, Horwitz SM, Hunt K, Lennox P, Mallucci P, Miranda RN, Munhoz AM, Swanson E, Turner SD, Firmani G, Sorotos M 2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCL. Aesthet Surg J 42(11):1262-1278, 2022. PMID: 35639805.
- Mouhayar EN, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome. JACC CardioOncol 3(5):752-755, 2021. PMID: 34988487.
- Hammond D, Montalban-Bravo G Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep 16(5):405-417, 2021. PMID: 34499330.
- Hammond D, Loghavi S Clonal haematopoiesis of emerging significance. Pathology 53(3):300-311, 2021. PMID: 33685721.
- Hammond D, Pemmaraju N Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am 34(3):565-574, 2020. PMID: 32336420.
Abstracts
- Hammond D, Kadia TM, DiNardo CD, Konopleva M, Short NJ, Daver N, Ravandi F, Pemmaraju N, Jabbour E, Chien K, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. None, 2021. PMID: None.
- Chua CC, Hammond D, Kent A, Tiong IS, Ong DM, Konopleva M, Pollyea D, Dinardo CD, Wei AH. Treatment Free Remission After Ceasing Venetoclax-based Therapy in Responding Patients with Acute Myeloid Leukemia. None, 2021. PMID: None.
- Hammond D, Sasaki K, Geppner A, Haddad F, Mohamed S, Rivera D, Siddiqui M, Alwash Y, Ramos Perez J, Morita K, Kim K, Pierce S, Gutierrez C, Pemmaraju N, Borthakur G, Dinardo CD, Ravandi F, Garcia-Manero G, Kantarjian H, Kadia TM. Contemporary Outcomes for Adults with AML Requiring ICU Admission. None, 2021. PMID: None.
- Hammond D, Loghavi S, Konopleva M, Kadia TM, Daver N, Ohanian M, Issa GC, Alvarado Y, Montalban-Bravo G, Garcia-Manero G, Borthakur G, Ravandi F, Takahashi K, Kantarjian H, DiNardo CD. Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. None, 2020. PMID: None.
- Guerra V, Ramos Perez J, Hammond D, Chien K, Kanagal-Shamanna R, Naqvi K, Sasaki K, Paul S, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Outcomes of Chronic Myelomonocytic Leukemia after Hypomethylating Agent Failure. None, 2020. PMID: None.
- Hammond D, DiNardo CD, Konopleva M, Borthakur G, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Paul S, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. None, 2020. PMID: None.
- Teichman J, Hammond D, Fenech S, Sholzberg M. Effect of Direct Oral Anticoagulants on Fibrinogen Induced Pseudoparaproteinemia. None, 2018. PMID: None.
- Hammond D, Jamali M, Wells RA, Zhang L, Mamedov A, Lenis M, Buckstein R. Impact of Bone Marrow Fibrosis in MDS Patients Treated with Azacitidine. None, 2016. PMID: None.
- Hammond D, Saidenberg E, Tinmouth A. Single Centre Experience with Rituximab in the Treatment of Inhibitor‐Associated Hemostatic Disorders. None, 2015. PMID: None.
Letters to the Editor
- Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
- Nasnas, PE, Ling, J, Gerstein, YS, Wang, S, Loghavi, S, Hammond, DE, Montalban Bravo, G, Senapati, J, Pemmaraju, N, Corredor, J, Pierce, S, Roth, M, Ravandi-Kashani, F, Cuglievan, B, Kadia, TM, DiNardo, C. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes. Clinical Lymphoma, Myeloma and Leukemia 24: 732-735, 2024.
- Montalban Bravo, G, Rodriguez-Sevilla, JJ, Swanson, DM, Kanagal Shamanna, R, Hammond, DE, Chien, KS, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
Grant & Contract Support
| Title: | 2022-0187: A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis |
| Funding Source: | Pulmocide |
| Role: | PI |
| Title: | Measurable residual disease detection using single-cell multiomics in patients with acute myeloid leukemia |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
Patient Reviews
CV information above last modified October 31, 2024